Scott L. Charland

1.2k total citations
34 papers, 959 citations indexed

About

Scott L. Charland is a scholar working on Economics and Econometrics, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Scott L. Charland has authored 34 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 10 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Surgery. Recurrent topics in Scott L. Charland's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Lipoproteins and Cardiovascular Health (7 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). Scott L. Charland is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Lipoproteins and Cardiovascular Health (7 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). Scott L. Charland collaborates with scholars based in United States, France and Sweden. Scott L. Charland's co-authors include S Follin, Michael H. Torosian, Daniel M. Witt, Sarah A. Spinler, Eric J. Stanek, Edward P. Armstrong, James J. Nawarskas, Eric G. Boyce, Stanley Goldfarb and Mark J. Cziraky and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Cancer.

In The Last Decade

Scott L. Charland

32 papers receiving 907 citations

Peers

Countries citing papers authored by Scott L. Charland

Since Specialization

Citations

This map shows the geographic impact of Scott L. Charland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott L. Charland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott L. Charland more than expected).

Fields of papers citing papers by Scott L. Charland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott L. Charland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott L. Charland. The network helps show where Scott L. Charland may publish in the future.

Co-authorship network of co-authors of Scott L. Charland

This figure shows the co-authorship network connecting the top 25 collaborators of Scott L. Charland. A scholar is included among the top collaborators of Scott L. Charland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott L. Charland. Scott L. Charland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus 2023 ·Diabetes Therapy ·(unknown), (unknown), (unknown), (unknown), Mihail Samnaliev, (unknown), Scott L. Charland, (unknown), Ronald Preblick	0
2	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study 2014 ·European Journal of Clinical Pharmacology ·(unknown), Jean‐Philippe Collet, Jean‐Sébastien Hulot, Jérémie Abtan, (unknown), Mathieu Kernéis, Johanne Silvain, Guillaume Cayla, Stephen O’Connor, Olivier Barthélémy, Farzin Beygui, Sophie Galier, Delphine Brugier, Eric J. Stanek, Scott L. Charland, Vanessa Gallois, Gilles Montalescot	10
3	Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits 2013 ·Current Medical Research and Opinion ·Sze Man Tse, Scott L. Charland, Eric J. Stanek, Vivian Herrera, Seth Goldfarb, Augusto A. Litonjua, Scott T. Weiss, Ann Chen Wu	20
4	PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL 2012 ·Journal of the American College of Cardiology ·Scott L. Charland, Barnabie Agatep, Robert S. Epstein, Felix W. Frueh, Vivian Herrera, James J. Devlin, H. Robert Superko, Eric J. Stanek	8
5	Abstract 16675: Assessment of Initial U.S. Dabigatran Utilization and Short-Term Persistence 2011 ·Circulation ·Eric J. Stanek, Barnabie Agatep, Vivian Herrera, (unknown), Bruce J. Schrader, Donald G. Pittman, Felix W. Frueh, Scott L. Charland	4
6	Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events 2008 ·Journal of clinical lipidology ·Scott L. Charland, Mark J. Cziraky, Ralph Quimbo, Richard H. Karas, William Insull, Michael H. Davidson, Eric J. Stanek	6
7	Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed? 2007 ·Clinical Therapeutics ·Chaitanya Sarawate, Mark J. Cziraky, Eric J. Stanek, Vincent J. Willey, John Corbelli, Scott L. Charland	10
8	Burden of illness of hepatitis C from a managed care organization perspective 2004 ·Current Medical Research and Opinion ·Edward P. Armstrong, Scott L. Charland	24
9	The Effect of Sepsis During Parenteral Nutrition on Hepatic Microsomal Function in Rats 2002 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Roland N. Dickerson, Scott L. Charland	1
10	Effectiveness and Economic Impact Associated With a Program for Outpatient Management of Acute Deep Vein Thrombosis in a Group Model Health Maintenance Organization 2000 ·Archives of Internal Medicine ·(unknown), Scott L. Charland, Daniel M. Witt	76
11	Acute Pain Management: Operative or Medical Procedures and Trauma 1997 ·Annals of Pharmacotherapy ·S Follin, Scott L. Charland	388
12	Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay 1997 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Judy W.M. Cheng, Scott L. Charland, Leslie M. Shaw, Sidney Kobrin, Stanley Goldfarb, Eric J. Stanek, Sarah A. Spinier	24
13	The effect of timing of single-dose transplacental ampicillin-sulbactam therapy for prevention of neonatal group B streptococcal colonization and bacteremia in a rabbit model 1996 ·American Journal of Obstetrics and Gynecology ·Robert S. McDuffie, (unknown), Scott L. Charland, Ronald S. Gibbs	3
14	The Effect of Insulin-like Growth Factor-1 on Protein Metabolism and Hepatic Response to Endotoxemia in Parenterally Fed Rats 1995 ·Journal of Surgical Research ·Roland N. Dickerson, (unknown), Scott L. Charland, R. Gregg Settle, T. Peter Stein, David A. Kuhl, (unknown)	20
15	Effect of glutamine on tumor and host growth 1995 ·Annals of Surgical Oncology ·(unknown), Scott L. Charland, Michael H. Torosian	30
16	Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia 1995 ·Surgery ·(unknown), Scott L. Charland, Michael H. Torosian	31
17	Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma 1994 ·The American Journal of Surgery ·(unknown), (unknown), (unknown), R. J. Wilson, Samuel E. Wilson, Scott L. Charland, John H. Rodman, Bradley A. Boucher	22
18	Effect of Protein‐Calorie Malnutrition on Methotrexate Pharmacokinetics 1994 ·Journal of Parenteral and Enteral Nutrition ·Scott L. Charland, David J. Bartlett, Michael H. Torosian	16
19	Review: The Effect of Parenteral Nutrition on Hepatic Cytochrome P‐450 1994 ·Journal of Parenteral and Enteral Nutrition ·(unknown), Scott L. Charland	7
20	Growth hormone, insulin, and somatostatin therapy of cancer cachexia 1994 ·Cancer ·(unknown), Michael H. Torosian, Scott L. Charland	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact